Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation

BeiGene, Hengrui Head Local R&D Push

Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.

China flag with pills (Pink Sheet Perspectives)
2021 CHINA NEW DRUG APPROVALS SHOW DOMESTICS CATCHING UP WITH MNCS • Source: Alamy

Regulatory clearances for two CAR-T therapies and one innovative antibody-drug conjugate during 2021 highlighted the acceleration of new drug approvals in China.

Throughout the year, the country’s drug approval agency the National Medical Products Administration (NMPA) granted the green light to a total of 43 innovative new therapies, with oncology products continuing to dominate

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Asia